SN-38 induces cell cycle arrest and apoptosis in human testicular cancer

European Urology

Volumn 42, Issue 4, 2002, Pages 390-397

  Ueno, Munehisa ^a   Nonaka, Shoichi ^a   Yamazaki, Ryuta ^b   Deguchi, Nobuhiro ^a   Murai, Masaru ^c  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bax; Cell cycle; SN 38; Testicular carcinoma

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA; DRUG DERIVATIVE; ETOPOSIDE; IRINOTECAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLIN E; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MALE; NICK END LABELING; TESTIS TUMOR; WESTERN BLOTTING; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN CELL; PRIORITY JOURNAL; TESTIS CANCER; TESTIS CELL; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL LINE; CISPLATIN; DNA; ETOPOSIDE; G1 PHASE; HUMANS; IN SITU NICK-END LABELING; MALE; TESTICULAR NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0036793893     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00321-4     Document Type: Article

References (31)

1. Power DA, Brown RSD, Brock CS, Payne HA, Majeed A, Babb P. Trends in testicular carcinoma in England and Wales, 1971-1999. BJU Int 2001;87:361-5.
2. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81.
3. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-53.
4. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosphamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
5. Droz JP, Culine S, Biron P, Kramar A. High-dose chemotherapy in germ-cell turnouts. Ann Oncol 1996;7:997-1003.
6. Margolin BK, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, et al. Treatment of germ cell cancer with two cycle of high-dose ifosphamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996;14:2631-7.
7. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:107-19.
8. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998;4:743-53.
9. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988;21:71-4.
10. Miki T, Sawada M, Nonomura N, Kojima Y, Okuyama A, Maeda O, et al. Antitumor effect of CPT-II, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol 1997;31:92-6.
11. Miki T, Nomoto T, Nakagawa S, Nakao M, Nonomura N, Takada T, et al. The salvage chemotherapy for refractory testicular cancer with novel anticancer agents. Acta Urol Jpn 1999;45:811-4 (English abstract).
12. Ueno M, Nakashima J, Ohigashi T, Deguchi N, Ban S, Akita M, Murai M. Establishment of testicular carcinoma cell line producing alpha-fetoprotein. BJU Int 2001;88:611-21.
13. Harasawa R, Mizusawa H, Nozawa K, Nakagawa T, Asada K, Kato I. Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNA intergenic spacer regions. Res Microbiol 1993;144:489-93.
14. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994;218:314-9.
15. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
16. Aoyagi Y, Kobunai T, Utsugi T, Oh-hara T, Yamada Y. In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerase I and II. Jpn J Cancer Res 1999;90:578-87.
17. Madden KR, Champoux JJ. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992;52:525-32.
18. INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997;88:1009-16.
19. Giaccone G, Gazdar AF, Beck H, Zunino F, Capriccio G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
20. Minagawa Y, Kigawa J, Itamochi H, Terakawa N. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer. Hum Cell 2001;14:237-43.
21. Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res 2001;61:4214-21.
22. Lauricella M, Giuliano M, Emanuele S, Carabillo M, Vento R, Tesoriere G. Increased cyclin E level in retinoblastoma cells during programmed cell death. Cell Mol Biol 1998;44:1229-35.
23. Mazumder S, Gong B, Almasan A. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells. Oncogene 2000;19:2828-35.
24. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225-36.
25. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993;53:1853-61.
26. Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M, Zhang W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 1998;16:1587-91.
27. Chresta CM, Masters JRW, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-41.
28. Guo B, Cao S, Toth K, Azrak RG, Rustum TM. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:718-24.
29. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
30. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
31. Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP. Mutations of the p53 gene are not detectable in human testicular tumors. Mod Pathol 1994;7:435-9.